Epidemiology and Symptomatology of Trichomoniasis

Rüttgers, H.

doi:10.1159/000269584

Cited by 4 publications

(2 citation statements)

References 3 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Reports on the therapeutic and prophylactic action of an antitrichomonal vaccine (SolcoTrichovac, Gynatren) were presented at a Symposium held in Basle, Switzerland in 1981 [11]. The initial clinical results seem very promising, even though the mechanism of action is still to a certain extent unclear.…”

Section: Introductionmentioning

confidence: 99%

A New Therapeutic Approach in Non-Specific Vaginitis

Boos¹,

Rüttgers²

1984

Gynäkol Geburtshilfliche Rundsch

Self Cite

View full text Add to dashboard Cite

182 patients suffering from symptomatic, mostly recurrent bacterial vaginitis were treated with SolcoTrichovac. The patients were mostly in the ‘under 25 years’ age group and almost 50% of them were on oral contraceptives. SolcoTrichovac immunotherapy resulted in a marked normalization of vaginal flora, reappearance of normal lactobacilli (71 %) and a drop in the vaginal pH as well as a significant decrease in subjective and objective clinical signs and symptoms (85 and 93%, respecitively).

show abstract

Section: Introductionmentioning

confidence: 99%

A New Therapeutic Approach in Non-Specific Vaginitis

Boos¹,

Rüttgers²

1984

Gynäkol Geburtshilfliche Rundsch

Self Cite

View full text Add to dashboard Cite

show abstract

“…We and other authors have reported ear lier on the initial clinical experience with the immunotherapeutic agent, Gynatren® (man ufactured by Solco Basle Ltd., CH-4127 Birsfelden, Switzerland), both in trichomon iasis and in nonspecific vaginitis [21,22], Vaccination with Gynatren leads to a spe cific immune response in serum [17], Very little information is available, however, on a local immune reaction in the form of secre tory immunoglobulins (slgA) in the vagina [18].…”

Section: Introductionmentioning

confidence: 99%

Bacterial Vaginitis: Protection against Infection and Secretory Immunoglobulin Levels in the Vagina after Immunization Therapy with Gynatren®

Rüttgers

1988

Gynecol Obstet Invest

Self Cite

View full text Add to dashboard Cite

In a prospective, randomized double-blind study the prophylactic effect of the immunotherapeutic agent, Gynatren®, against reinfection was investigated in 192 patients with bacterial vaginitis (95 treated with the active preparation versus 97 with placebo). In 30 and 25% of the patients in the two groups, respectively, it was the third or even more frequent infection in a period of 12 months. In a further 46 and 39%, respectively, it was the second infection in the course of a year. All the patients were given local treatment with tetracycline-amphotericin B vaginal suppositories and at the same time vaccinated with Gynatren or placebo. One month after the start of treatment, 85% of the patients in the active-treatment group and 83% in the placebo group were asymptomatic and free from pathogenic bacteria. After 3 months 78% in the active-treatment group and 60% in the placebo group were free from infection. After 6 months 76 and 40%, and after 12 months 75 and 37% of the women in the active-treatment and placebo groups, respectively, were free from clinical symptoms and pathogenic bacteria. These results correlated with the concentrations of local antibodies (secretory immunoglobulin) detectable in the vaginal secretion.

show abstract

Prevalence and risk factors of intestinal protozoan and helminth infections among pulmonary tuberculosis patients without HIV infection in a rural county in P. R. China

Chen

Wang

et al. 2015

Acta Tropica

View full text Add to dashboard Cite

Epidemiology and Symptomatology of Trichomoniasis

Cited by 4 publications

References 3 publications

A New Therapeutic Approach in Non-Specific Vaginitis

A New Therapeutic Approach in Non-Specific Vaginitis

Bacterial Vaginitis: Protection against Infection and Secretory Immunoglobulin Levels in the Vagina after Immunization Therapy with Gynatren®

Prevalence and risk factors of intestinal protozoan and helminth infections among pulmonary tuberculosis patients without HIV infection in a rural county in P. R. China

Contact Info

Product

Resources

About